De Novo Genome Assembly Global Market Report 2026

De novo genome assembly is the method of reconstructing a complete genome sequence from short DNA fragments without referencing an existing genome. It relies on overlapping sequences between fragments to accurately assemble the original genome. This technique is critical for studying organisms with unknown or highly variable genomes.

The essential components of de novo genome assembly include software and services. Software refers to bioinformatics tools that reconstruct genomes from sequencing data without relying on a reference genome, enabling analysis of novel or poorly characterized organisms. Organism types include human, animal, plant, microbial, and metagenomic or mixed samples, and technologies utilized include next-generation sequencing, third-generation sequencing, Sanger sequencing, and others. Applications include clinical diagnostics, agricultural genomics, environmental genomics, evolutionary biology, and more, serving academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users.

Tariffs have affected the de novo genome assembly market by increasing costs for importing advanced sequencing instruments, software tools, and reagents. Segments such as software and sequencing services are most impacted, particularly in regions like North America and Europe that depend on imported high-end sequencing technologies. While tariffs may slow adoption temporarily, they are encouraging local manufacturing, fostering development of cost-effective sequencing solutions, and driving innovation in genome assembly services.

The de novo genome assembly market research report is one of a series of new reports from The Business Research Company that provides de novo genome assembly market statistics, including de novo genome assembly industry global market size, regional shares, competitors with a de novo genome assembly market share, detailed de novo genome assembly market segments, market trends and opportunities, and any further data you may need to thrive in the de novo genome assembly industry. This de novo genome assembly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The de novo genome assembly market size has grown rapidly in recent years. It will grow from $1.99 billion in 2025 to $2.28 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing use of next-generation sequencing, growth of academic research initiatives, adoption of genome assembly software, rising demand in clinical diagnostics, development of plant and microbial genomics projects.

The de novo genome assembly market size is expected to see rapid growth in the next few years. It will grow to $3.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to integration of ai in genome assembly, expansion of cloud-based bioinformatics platforms, demand for rapid custom genome sequencing, growth in precision medicine applications, investment in evolutionary and environmental genomics. Major trends in the forecast period include automated genome assembly pipelines, cloud-based data analysis, high-throughput sequencing integration, custom bioinformatics services, visualization & annotation enhancements.

The increasing demand for personalized medicine is anticipated to drive the expansion of the de novo genome assembly market in the coming years. Personalized medicine involves medical treatments and therapies specifically tailored to individual patients based on their genetic profile, biomarkers, and distinct disease characteristics. This demand is rising owing to advancements in genomic technologies and molecular diagnostics, which allow treatments to be customized according to an individual's genetic makeup, enhancing outcomes and reducing side effects. De novo genome assembly supports personalized medicine by reconstructing an individual's genome from the ground up, facilitating the identification of unique genetic variants and structural changes that guide precision therapies, customized drug selection, and early disease intervention. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, including seven cancer therapies and three for other diseases and conditions. Consequently, the rising demand for personalized medicine is propelling the growth of the de novo genome assembly market.

Leading companies operating in the de novo genome assembly market are focusing on developing innovative solutions such as high-throughput genome assembly platforms to accelerate genome reconstruction and improve accuracy for complex and diverse organisms. High-throughput genome assembly platforms are advanced systems that combine long- and short-read sequencing data to rapidly reconstruct complete genomes with high precision, enabling researchers to generate contiguous assemblies faster and manage complex or repetitive genomic regions more efficiently than traditional methods. For example, in May 2024, Dovetail Genomics Inc., a US-based genomics technology company, introduced the AssemblyLINK Assay, a high-throughput genome assembly platform designed to accelerate genome assembly workflows and enhance the accuracy of de novo assemblies. The AssemblyLINK Assay integrates proprietary scaffolding technology with existing sequencing data to produce highly contiguous genome assemblies, simplifies data processing through streamlined computational pipelines, and supports a wide range of organisms, from plants and animals to microbial communities. Its distinctive features include compatibility with multiple sequencing platforms, reduction in manual intervention, and optimized performance for complex and large genomes, making it particularly valuable for biodiversity research and conservation genomics.

In May 2024, MedGenome Labs Pvt. Ltd., an India-based genomics and molecular diagnostics company focused on delivering de novo genome assembly services, formed a partnership with Pacific Biosciences of California Inc. (PacBio) to assist researchers in producing high-quality reference genomes and advancing genomic studies. Through this collaboration, MedGenome Labs Pvt. Ltd. and PacBio aim to aid researchers in generating top-tier reference genomes, promoting multiomics research, enabling thorough analysis of complex genomic regions, supporting the discovery of novel genes and regulatory elements, and speeding up the development of precision medicine and biotechnological innovations. Pacific Biosciences of California Inc. is a US-based company specializing in long-read DNA sequencing and genomic analysis platforms.

Major companies operating in the de novo genome assembly market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Illumina Inc., QIAGEN N.V., Novogene Corporation, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Medgenome labs pvt. Ltd, DNASTAR Inc., Nucleome Informatics Pvt Ltd, Seven Bridges Genomics, DNAnexus Inc., Strand Life Sciences Pvt. Ltd., BaseClear B.V., Dovetail Genomics LLC, SoftGenetics LLC, CosmosID Inc., Microba Life Sciences Ltd., GenomeScan B.V., BGI Genomics Co. Ltd., Macrogen Inc., SeqMatic LLC, NeuGen Biologicals.

North America was the largest region in the de novo genome assembly market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the de novo genome assembly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the de novo genome assembly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The de novo genome assembly market includes revenues earned by entities by service such as genome assembly sequencing, bioinformatics analysis, genome annotation, custom genome assembly, comparative genomics analysis, structural variant analysis, metagenome assembly, microbial genome assembly, plant genome assembly and animal genome assembly. The market value includes the value of related goods sold by the service provider or included within the service offering. The de novo genome assembly market also includes sales of sequencing instruments, library preparation kits, reagents, flow cells, sequencing chips, sample preparation systems, high performance computing servers, storage systems, genome assembly software packages. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

De Novo Genome Assembly Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses de novo genome assembly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for de novo genome assembly ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The de novo genome assembly market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Component: Software; Services
• 2) By Organism Type: Human; Animal; Plant; Microbial; Metagenomic Or Mixed Samples
• 3) By Technology: Next-Generation Sequencing; Third-Generation Sequencing; Sanger Sequencing; Other Technologies
• 4) By Application: Clinical Diagnostics; Agricultural Genomics; Environmental Genomics; Evolutionary Biology; Other Applications
• 5) By End-User: Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Hospitals And Clinics; Other End-Users
• Subsegments:
• 1) By Software: Sequence Alignment Software; Genome Assembly Software; Error Correction And Quality Control Software; Visualization And Annotation Software
• 2) By Services: Genome Sequencing Services; Data Analysis And Interpretation Services; Custom Genome Assembly Services; Consulting And Bioinformatics Support Services
• Companies Mentioned: Thermo Fisher Scientific Inc.; Eurofins Scientific SE; Illumina Inc.; QIAGEN N.V.; Novogene Corporation; Oxford Nanopore Technologies Ltd.; Pacific Biosciences of California Inc.; Medgenome labs pvt. Ltd; DNASTAR Inc.; Nucleome Informatics Pvt Ltd; Seven Bridges Genomics; DNAnexus Inc.; Strand Life Sciences Pvt. Ltd.; BaseClear B.V.; Dovetail Genomics LLC; SoftGenetics LLC; CosmosID Inc.; Microba Life Sciences Ltd.; GenomeScan B.V.; BGI Genomics Co. Ltd.; Macrogen Inc.; SeqMatic LLC; NeuGen Biologicals.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.